Home › Funds › Venrock Adviser, LLC › ELVN

Venrock Adviser, LLC position in ELVN

ENLIVEN THERAPEUTICS INC · Health Care

Venrock Adviser, LLC reported holding 526,331 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$26.7M, representing 0.81% of its reported portfolio and ranking #20 among its reported holdings. Venrock Adviser, LLC has disclosed ELVN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)526.33K sh
Reported value held$26.71M
Portfolio Weight0.81%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Venrock Adviser, LLC's ELVN position evolved

Venrock Adviser, LLC first disclosed a stake in ELVN in Q3 2023 at 2,954,902 shares (US$40.4M). The position peaked in Q3 2024 at 4,026,331 shares, worth US$102.8M. Across 12 filings, Venrock Adviser, LLC increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 526,331 shares valued at US$26.7M — a reduction of -1,200,000 shares quarter over quarter.. Notable position changes include a 36% increase in Q1 2024 (shares rose 33% over the following quarter), a 46% trim in Q1 2026 (shares rose 29% over the following quarter), a 70% trim in Q2 2026 (shares fell 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.95M $40.36M New
Q4 2023 2.95M $40.90M Hold
Q1 2024 4.03M $70.82M Add
Q2 2024 4.03M $94.10M Hold
Q3 2024 4.03M $102.83M Hold
Q4 2024 4.03M $90.59M Hold
Q1 2025 4.03M $79.24M Hold
Q2 2025 4.03M $80.77M Hold
Q3 2025 3.23M $66.04M Reduce
Q4 2025 3.23M $49.69M Hold
Q1 2026 1.73M $67.67M Reduce
Q2 2026 526.33K $26.71M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ELVN and 13F data

ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 67 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$326.4M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ELVN

All ELVN fund holders →

FAQ

How long has Venrock Adviser, LLC held ELVN?

Venrock Adviser, LLC has disclosed ELVN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Venrock Adviser, LLC's current position in ELVN?

As of Q2 2026, Venrock Adviser, LLC holds 526.33K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $26.71M, representing 0.81% of its reported portfolio and ranking #20.

Has Venrock Adviser, LLC been buying or selling ELVN?

In the latest 13F filing (Q2 2026), Venrock Adviser, LLC reduced its position in ELVN. The position peaked in Q3 2024 at 4.03M shares.

Which other funds hold ELVN?

Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 67 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.